As everyone knows, the pandemic COVID-19 is spreading in the whole world. The number of laboratory-confirmed cases reached 28,637,211 and that of the death cases was 917,404 in the world as of September 13 th , 2020. We sought to analyse the clinical characteristics, laboratory findings and therapy of some cases with COVID-19.
In this retrospective study, we extracted the data on 134 patients with laboratory-confirmed COVID-19 in Wuhan Xinzhou District People's Hospital from January 16 th to April 24 th , 2020. Cases were confirmed by real-time RT-PCR and abnormal radiologic findings. Outcomes were followed up until May 1 th , 2020.
Co-infection and severe underlying diseases made it easier for a case with COVID-19 to develop to be a severe one or reach an outcome of death. Age above 60 years old, male and symptoms such as fever, cough, chest tightness, headaches and fatigue were related to severe COVID-19 and an outcome of death. In addition, higher temperature, blood leukocyte count, neutrophil count, C-reactive protein level, D-dimer level, alanine aminotransferase activity, aspartate aminotransferase activity, α -hydroxybutyrate dehydrogenase activity, lactate dehydrogenase activity and creatine kinase activity were also related to severe COVID-19 and an outcome of death, and so was lower lymphocyte count. Administration of gamma globulin seemed helpful for reducing the mortality of patients with severe COVID-19, however the P value was greater than 0.05 (P=0.180), which mean under the same condition, studies of larger samples are needed in the future.
Multiple factors were related to severe COVID-19 and an outcome of death. Administration of gamma globulin seemed helpful for reducing the mortality of severe cases. More related studies are needed in the future.